Literature DB >> 9358198

A comparison of the pharmacokinetics of meropenem after intravenous administration by injection over 2, 3 and 5 minutes.

H K Jones1, H C Kelly, M Hutchison, R A Yates, F Ross, C Lomax, S Freestone, D Webb.   

Abstract

The pharmacokinetics of meropenem were determined in 9 healthy volunteers after the administration of 1 g dose by injection over 2, 3 or 5 min. Peak plasma concentrations were not significantly different across the three rates of administration and, due to the finite time required for complete mixing of the blood in the central compartment, did not always occur at the end of the injection. Overall exposure to meropenem was unchanged by the more rapid rates of administration. Plasma clearance, terminal half-life and volume of distribution were virtually unchanged. Within 10 min after the start of the injection, the plasma concentrations from all three injections were very similar indicating that dosing over 2, 3 or 5 min would result in similar antimicrobial cover and, therefore, comparable efficacy. Comparison of the data derived from the three injections indicated that rapid administration of meropenem did not appreciably alter its disposition pharmacokinetics. Tolerability of meropenem was unchanged with the more rapid administration rate.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9358198     DOI: 10.1007/BF03189806

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  23 in total

1.  Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem.

Authors:  L A Burman; I Nilsson-Ehle; M Hutchison; S J Haworth; S R Norrby
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

2.  Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.

Authors:  P H Hinderling; E R Garrett
Journal:  J Pharmacokinet Biopharm       Date:  1976-06

3.  Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study.

Authors:  S R Norrby; B Vandercam; T Louie; V Runde; B Norberg; M Anniko; F Andrien; M Baudrihaye; E Bow; L A Burman
Journal:  Scand J Infect Dis Suppl       Date:  1987

Review 4.  Efficacy and safety of imipenem/cilastatin: a review of worldwide clinical experience.

Authors:  C Wang; G B Calandra; M A Aziz; K R Brown
Journal:  Rev Infect Dis       Date:  1985 Jul-Aug

5.  A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min.

Authors:  H C Kelly; M Hutchison; S J Haworth
Journal:  J Antimicrob Chemother       Date:  1995-07       Impact factor: 5.790

6.  Influence of sample site on blood concentrations of ICI 35868.

Authors:  E Major; C Aun; P M Yate; T M Savege; A J Verniquet; H Adam; E J Douglas
Journal:  Br J Anaesth       Date:  1983-05       Impact factor: 9.166

7.  The disposition and metabolism of meropenem in laboratory animals and man.

Authors:  M P Harrison; S R Moss; A Featherstone; A G Fowkes; A M Sanders; D E Case
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

8.  Pharmacokinetic evaluation of ICI 35 868 in man. Single induction doses with different rates of injection.

Authors:  H K Adam; L P Briggs; M Bahar; E J Douglas; J W Dundee
Journal:  Br J Anaesth       Date:  1983-02       Impact factor: 9.166

Review 9.  Meropenem: a microbiological overview.

Authors:  J R Edwards
Journal:  J Antimicrob Chemother       Date:  1995-07       Impact factor: 5.790

10.  Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment.

Authors:  A Leroy; J P Fillastre; F Borsa-Lebas; I Etienne; G Humbert
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

View more
  3 in total

Review 1.  Meropenem: a review of its use in patients in intensive care.

Authors:  M Hurst; H M Lamb
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

2.  Scaling beta-lactam antimicrobial pharmacokinetics from early life to old age.

Authors:  Dagan O Lonsdale; Emma H Baker; Karin Kipper; Charlotte Barker; Barbara Philips; Andrew Rhodes; Mike Sharland; Joseph F Standing
Journal:  Br J Clin Pharmacol       Date:  2018-11-26       Impact factor: 4.335

3.  Meropenem. A pharmacoeconomic review of its use in serious infections.

Authors:  S M Holliday; P Benfield
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.